I congratulate Dr Sarasin and his colleagues for their detailed cost-effectiveness analysis of antiplatelet therapy in cerebrovascular disease.1 They conclude that the combination of aspirin and dipyridamole is "more effective and less costly than aspirin alone." However, this conclusion hinges on 2 key assumptions that are flawed, particularly for medical care in the United States.
Heidebrink JL. Is Treatment With Aspirin Combined With Dipyridamole Really More Cost-effective Than Aspirin Alone?. Arch Intern Med. 2001;161(9):1236. doi: